QualityStocks

[QualityStocks]

Vivos Therapeutics, Inc.’s Technology Offers Fresh Hope to Sleep Apnea Sufferers

-Obstructive Sleep Apnea (“OSA”) is a pervasive disorder impacting the lives of up to 1 billion people globally and approximately 54 million Americans. OSA has been linked to increased rates of cancer, hypertension, cardiovascular disease, ADHD, Alzheimer’s, diabetes, dementia, and ultimately—up to 10-year shorter lifespans.
-Current front-line treatment options such as CPAP are intrusive and must be used every night for life in order to be effective. Surgical options and implants can be risky and expensive.
-The Vivos System is the first treatment modality for mild to moderate OSA which has demonstrated the ability to remodel and enhance the size, shape, and function of the human airway—all within a relatively short time and without the need for lifetime intervention and treatment.

For chronic insomniacs and sleep apnea sufferers the world over, help has finally arrived. A revolutionary remedy developed by Vivos Therapeutics represents a possible solution to the frustrating and potentially life-threatening condition known as Obstructive Sleep Apnea (“OSA”). This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development—the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices. Over the typical 18 to 24 month course of treatment, we believe the patient’s upper airway is remodeled and enhanced, thereby reducing the tissue obstructions that gave rise to the OSA. Thus, Vivos technology represents the first true hope of an effective and lasting non-surgical OSA solution that in most cases, doesn’t require a lifetime of treatment intervention. For the first time, the salutation “good night” will truly mean a good night for these sufferers.

Years ago, before we understood just how deadly and debilitating OSA truly was, many people actually poked fun at those who suffered from it. Some erroneously still consider it to be a condition that only affects overweight middle-aged males. Today, however, we know that patients of all ages, ethnicities, BMI scores, and demographics are at risk. Even mild-to-moderate sufferers are known to be at much greater risk for virtually all of the major chronic diseases plaguing modern man—cancer, diabetes, hypertension, cardiovascular disease, stroke, Alzheimer’s, ADHD, dementia, fibromyalgia, and more. The latest research has highlighted the key role that a good night’s rest plays in our overall health and wellness—both mentally and physically. For those with OSA, it can be impossible to experience the rest and rejuvenation that comes from a good night’s rest.

The severity of OSA is typically measured by what is known as the Apnea Hypopnea Index or AHI. Simply put, this index tallies up the number of times per hour during the night that the patient stops breathing for at least 10 seconds (an apnea). Five time or less per hour is considered normal. Between five and fifteen times is considered mild. Between 15 and 30 is considered moderate, and 30 or more is considered severe. Most patients think of snoring when they think of OSA. The two conditions are related but different, and while almost all OSA patients snore, not all snorers have OSA. Only a polysomnogram or home sleep test can tell for sure. Those tests will measure a number of parameters that go on during sleep, and from that data an AHI score can be derived.

The latest diagnostic technology from SleepImage, which recently received FDA clearances, can actually detect and render a medical diagnosis for OSA via a single sensor device worn on the wrist. The technology uses the latest advances in cardiopulmonary coupling to derive not only an AHI score, but also provide many other important indicators of sleep quality. Given the fact that 80% or more of all patients believed to have OSA remain undiagnosed and untreated, the growing ability to screen and identify potential sufferers is creating more and more patients seeking treatment. As this happens, Vivos Therapeutics is well positioned to be the treatment of choice.

The current medical “Gold Standard” for the non-surgical treatment of OSA is continuous positive airway pressure (or CPAP). These systems consist of a machine that blows air through a tube connected to a face mask worn by the sleeper. They are generally effective at alleviating symptoms, but can be uncomfortable, poorly tolerated and obtrusive to use and maintain. In addition, they can affect the quality of sleep of both sufferers and their partners. In stark contrast, the Vivos System is simple to use and comfortable to wear. It doesn’t make noise or affect the person laying next to the patient. It doesn’t harbor mold or bacteria that can lead to respiratory infections and pneumonia. Most patients report an improvement in their rest and overall energy levels within days or a few short weeks of treatment.

The remodeling and airway enhancement effects of the Vivos System are referred to as Pneumopedics(R). Think of it like the three-dimensional expansion of a balloon when air is blown into it. Pneumopedics is a natural process induced by the company’s proprietary biomimetic technology, which is believed to remodel airway tissues to increase their size, shape and capacity. The system was developed using expertise drawn from a number of medical and dental specialties, particularly dental practitioners who have completed advanced training in craniofacial sleep medicine. Unlike many other approaches, the Vivos System aims for a lasting resolution by targeting the root cause of obstructive sleep apnea: abnormal development of the craniofacial anatomy.

Central to the success of the company is its ability to recruit and train dentists in the proper integration of the Vivos System into their practices. The company currently has over 1,350 trained providers throughout North America, with others scattered around the world. The company regularly conducts online continuing education and other training broadcasts that expose this revolutionary technology to dentists and other healthcare providers on a global scale. This year to date the company has presented at least some portion of its overall continuing education program on airway development and the central role of dentistry to over 47,000 clinicians and staff members worldwide.

For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS